The feasibility study evaluates the Hemopurifier in patients with advanced solid tumors who have stopped responding to standard anti-PD-1 immunotherapies. Researchers observed consistent reductions in tumor-derived extracellular vesicles and specific microRNAs associated with cancer progression. Furthermore, participants showed improvements in immune-related lab ratios and an increase in T-cell populations, including CD4 and CD8 variants, which generally persisted through an eight-week follow-up period.

James Frakes, CEO and CFO of Aethlon Medical, noted that the replication of these directional changes across two cohorts strengthens the scientific rationale for the program. The company is now enrolling the third and final cohort to determine if the biological shifts represent a clear dose-response relationship. While the Hemopurifier holds FDA Breakthrough Device Designation, the company emphasizes that these are descriptive observations from an early-stage study; the trial was not designed to measure clinical efficacy, and results regarding patient outcomes remain pending.